глукофаж предијабетес хр

Glucophage® pre-diabetes

Original metformin

Treatment of pre-diabetes

By timely intervention, patients can reduce their risk of progression to type 2 diabetes, 4 as well as the complications that can lead to serious health problems. 5 In 2017, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved Glucophage® XR (Extended Release Formulation) to reduce the risk or delay the onset of type 2 diabetes in overweight, obese patients with impaired glucose tolerance and / or impaired fasting glucose and / or elevated glycosylated haemoglobin, when they failed with intensive lifestyle changes of three to six months.6 Since April 2018, the antidiabetic indication for Glucophage XR has been approved in 23 countries worldwide, including RN Macedonia, Mexico, Brazil, Russia, Egypt and the Philippines.
  1. NICE guideline ph38: Type 2 diabetes: prevention in people at high risk. Published 12 July 2012. Available at: https://www.nice.org.uk/guidance/ph38/chapter/8-glossary#pre-diabetes. Last accessed March 2018.
  2. ADA (American Diabetes Association). Standards of Medical Care in Diabetes. Diabetes Care. 2013;36(1):S11 66.
  3. IDF (International Diabetes Federation). (2012). Clinical Guidelines Task Force: Global guideline for the management of type 2 diabetes. Available at: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes Last accessed March 2018.
  4. DPP Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346:393 403.
  5. ESC (European Society of Cardiology). Diabetes, Prediabetes and Cardiovascular Diseases with the EASD. Available at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Diabetes-Pre-Diabetes-and-Cardiovascular-Diseases-developed-with-the-EASD. Last accessed November 2017
  6. SMC. UK 2017. Glucophage SR 500mg, 750mg and 1000mg prolonged release tablets.